Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Celanese Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $5.2B | |
|---|---|---|
| Revenue (ttm) | 9.7B | |
| Net income (ttm) | -1.2B | |
| EPS (ttm) | -$10.7 | |
| Shares out | 109.7M | |
| P/E (forward) | 7.2x | |
| Dividend | $0.12 (0.25%) | |
| Volume | 699,949 | |
| Beta | 0.76 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $8.54B | $9.67B | $10.93B | $10.27B | $9.54B | +2.8% |
| Gross profit | $2.68B | $2.38B | $2.58B | $2.34B | $1.95B | -7.6% |
| Operating income | $1.95B | $1.38B | $1.67B | $-720.0M | $-786.0M | — |
| Net income | $1.89B | $1.89B | $1.94B | $-1.54B | $-1.17B | — |
| EPS (diluted) | $16.86 | $17.34 | $17.76 | $-14.11 | $-10.64 | — |
| EBITDA | $2.72B | $2.30B | $2.61B | $503.0M | $335.0M | -40.7% |
| R&D | $86.0M | $112.0M | $146.0M | $130.0M | $125.0M | +9.8% |
| SG&A | $633.0M | $824.0M | $1.08B | $1.03B | $899.0M | +9.2% |
Recent company headlines from major financial publishers.
Global industrial demand and automotive assembly rates rebound robustly, driving strong volume growth for Engineered Materials. Acetyl Chain pricing remains elevated as Western Hemisphere supply chain advantages persist. Rapid debt retirement reduces annual interest expense, accelerating EPS growth and unlocking multiple expansion toward historical peak levels.
Celanese executes on its core operational strategy: modest revenue growth, steady recovery in Engineered Materials margins via footprint actions, and resilient cash generation from the Acetyl Chain. Free cash flow is disciplined and deployed exclusively to debt reduction, steadily lowering financial leverage and driving intrinsic value convergence to $76.31.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 7.4% | $83.4 | $85.8 | $88.3 | $91.2 | $94.3 |
| 7.9% | $77.7 | $79.7 | $81.8 | $84.2 | $86.7 |
| 8.4% | $72.9 | $74.5 | $76.3 | $78.2 | $80.3 |
| 8.9% | $68.7 | $70.1 | $71.6 | $73.2 | $74.9 |
| 9.4% | $64.9 | $66.1 | $67.4 | $68.8 | $70.3 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
